oncomed manufacturing — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Oncomed Manufacturing is a key European CDMO within the medac Group, focusing on the complex manufacturing of injectable drugs, including cytostatics, small molecules, biologics, and antibody-drug conjugates (ADCs). With two facilities in Europe and a total capacity of up to 11,000 liters, it offers comprehensive services across the drug lifecycle, supported by a strong quality system compliant with major global regulatory standards. The company is recognized for its expertise in handling highly potent compounds and modern dosage forms, positioning it as a strategic partner for pharmaceutical companies seeking scalable, high-quality manufacturing solutions.

Oncology

Technology Platform

Specialized CDMO platform for sterile injectable pharmaceuticals. Core technologies include aseptic filling, lyophilization, sterilization, and handling of highly potent compounds (HPAPIs). Capabilities cover small molecules, biologics, and antibody-drug conjugates (ADCs) in dosage forms such as vials, pre-filled syringes, and cartridges.

Opportunities

Strong growth in the biologics and ADC markets drives demand for specialized sterile manufacturing.

The global trend toward pharmaceutical outsourcing and the rise of virtual biotech companies create a expanding client base for established CDMOs.

Rebranding under the medac name may enhance market recognition and attract new partnerships.

Risk Factors

High operational risk associated with sterile manufacturing, where any contamination or deviation can lead to severe regulatory and financial consequences.

Intense competition in the CDMO sector pressures pricing and requires continuous capital investment.

Dependency on the clinical success of client programs and potential client concentration are inherent business risks.

Competitive Landscape

Oncomed competes in the global CDMO market for sterile injectables against large, diversified players (e.g., Lonza, Catalent, Recipharm) and specialized oncology-focused manufacturers. Its competitive advantages include its HPAPI/oncology expertise, flexible scale-up capacity, and strong regulatory track record with major health authorities. Being part of a mid-sized, focused pharma group (medac) provides stability but may limit its scale compared to larger pure-play CDMOs.

More companies in Oncology (General) →More companies in Czech Republic →